Genprex stock rises on Roche Diagnostics collaboration
Investing.com -- Genprex Inc. (NASDAQ:GNPX) shares rose 3% Monday following the announcement of a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials.
Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓
Investing.com -- Genprex Inc. (NASDAQ:GNPX) shares rose 3% Monday following the announcement of a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials. The collaboration aims to refine patient identification using TROP2 as a biomarker, building on the company’s preclinical and clinical data. Genprex’s research showed that high TROP2 H-scores and low PTEN H-scores predicted patient response in preclinical studies and correlated with longer progression free survival in clinical studies for NSCLC patients with TROP2 H-scores above 100 and PTEN H-scores below 100.
Read the full report at Investing.com · Stock Market ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Investing.com -- Genprex Inc. (NASDAQ:GNPX) shares rose 3% Monday following the announcement of a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials.
- How widely is it covered?
- 1 outlet, average source rating 6.0/10.
- When was it last updated?
- 4m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Genprex stock rises on Roche Diagnostics collaboration
Sources1TypeCoverageInvesting.com · Stock Market